#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hidradenitis Malignant neoplasm of choroid Homocystinuria Precursor T-lymphoblastic lymphoma/leukaemia recurrent Nodal marginal zone B-cell lymphoma Dementia with Lewy bodies White matter lesion Conjunctivitis allergic Von Willebrand's disease Immunoglobulin G4 related disease Waldenstrom's macroglobulinaemia Philadelphia chromosome positive Urea cycle disorder Polycystic liver disease Adrenocortical carcinoma More trials…

    Learn about Rare Diseases

    Mucous membrane pemphigoid – Treatment Hereditary angioedema – Life with Disease Piriformis syndrome – Life with Disease Antisynthetase syndrome – Trials in Disease CADASIL Cytokine release syndrome – Basic Information Prolymphocytic leukaemia Progressive supranuclear palsy – Basic Information Netherton’s syndrome – Diagnostics Cystic fibrosis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ROPINIROLE Bbp-398 LY3372993 DIMENHYDRINATE Emavusertib Pimozide Csm-Gw Treg02 Upacicalcet Sodium Hydrate GSKVX000000034792 Givinostat Valproic Acid SIGVOTATUG VEDOTIN Gadobenate Dimeglumine Daplusiran Raludotatug Deruxtecan Dexchlorpheniramine Basimglurant BI-1607 20-HYDROXYECDYSONE More therapies…

    Learn about Your Condition

    Malignant mast cell neoplasm Cortisol abnormal Hypophosphatasia Deafness Cataract Alport's syndrome Endometriosis Meningorrhagia Graves' disease Androgenetic alopecia Biliary tract disorder Choreoathetosis Neuropathic arthropathy Pulmonary sarcoidosis Neonatal hyperglycaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant melanoma stage III

  • Study Comparing Ipilimumab and Nivolumab to Nivolumab Alone for Patients with Resectable Stage III Melanoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage III
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    Sweden

  • Study of Regorafenib with BRAF/MEK-Inhibitor Combination for Patients with Advanced Melanoma After Previous Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Malignant melanoma stage III
    Investigated Drugs:
    • Regorafenib
    Belgium

  • Study of LTX-315 and Pembrolizumab for Patients with Resectable Stage III-IV Melanoma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Malignant melanoma stage III
    Investigated Drugs:
    • Ruxotemitide
    Norway

  • Phase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Malignant melanoma stage III
    Investigated Drugs:
    • Nivolumab
    • Pembrolizumab
    Sweden

  • A study of ipilimumab and nivolumab to observe immune system changes in patients with unresectable stage III or IV melanoma

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Malignant melanoma stage III
    Investigated Drugs:
    • Ipilimumab
    The Netherlands

  • Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Malignant melanoma stage III
    Investigated Drugs:
    • Enomimeran
    • Gindameran
    • Ontasameran
    Germany Italy Poland Spain
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!